Cannabidiol seems to represent a mechanistically different and less side-effect prone antipsychotic compound for the treatment of schizophrenia.

A recent systematic review published in Schizophrenia Research in March 2015 finds that the use of cannabidiol (CBD), a phytocannabinoid (i.e. a cannabinoid found in the cannabis plant) may be helpful in the management of psychotic symptoms (which are characterized by a “loss of contact with reality”), such as those experienced by individuals with schizophrenia.

Cannabidiol seems to represent a mechanistically different and less side-effect prone antipsychotic compound for the treatment of schizophrenia.